Browse studies

Find your next paid study

27,293 recruiting studies available now

A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effect…

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaAcute Leukemia of Ambiguous Lineage

Estimated

~$150 – $3,000

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT06177067

Phase 2

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses With Placebo as Treatment for Rhinovirus (RV) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the seve…

Rhinovirus Infection

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Altesa Biosciences, Inc.NCT07610395

Phase 3

An Open-Label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients With Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/Week and 120 mg/kg/Week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)

This study is designed to compare two different weekly doses of a medicine called Alpha1-Proteinase Inhibitor given by injection under the skin with the standa…

Alpha 1 Antitrypsin Deficiency

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Grifols Therapeutics LLCNCT07555483

Phase 2

A Phase 2, Open-Label, Multicenter, Randomized Trial Evaluating the Efficacy and Safety of Different Schedules of Neoadjuvant Pembrolizumab and Porustobart in Patients With Resectable pMMR/MSS Colon Cancer

The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon ca…

Colon Cancer

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Solstice Oncology, Inc.NCT07808151

Phase 1

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, th…

Healthy VolunteersAlzheimer DiseaseAmyloid+1 more

Estimated

~$500 – $11,250

Actual pay is set by the research site.

Eli Lilly and CompanyNCT07787182

Identification Of Lung Cancer In Never-Smoking Individuals Using A Non-Invasive Volatile Organic Compound (VOCs) Biological Platform With Urine Specimens

The goal of this observational study is to learn whether a urine-based test that measures volatile organic compounds (VOCs) can help detect lung cancer in peop…

Lung Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

Thomas Jefferson UniversityNCT07871656

Observational

Support Towards Addiction Recovery for Individuals With Criminal Legal System Involvement: The STAR Project

The goal of this clinical trial is to determine whether a new, paired coaching intervention improves outcomes for individuals with criminal legal system involv…

Addiction

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Martha TillsonNCT07596251

Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy

Background: Turner Syndrome, galactosemia, and premature ovarian insufficiency are all conditions that may make it very hard or impossible for a person to bec…

Turner SyndromePost-menarcheal AdolescentsOvarian Disfunction+3 more

Estimated

~$10 – $675

Actual pay is set by the research site.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT04948658

Phase 3

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine)…

Ulcerative Colitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AbbVieNCT07071519

Phase 2

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with pl…

ObesityOverweight

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Eli Lilly and CompanyNCT07890376

Phase 1

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal…

Hepatic Impairment

Estimated

~$500 – $11,250

Actual pay is set by the research site.

AstraZenecaNCT07546760

Phase 2

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSC…

Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07154290